High Vasopressor Doses Do Not Indicate Delayed Septic Shock Treatment Timing

Authors Žiga Kalamar, Giovanni Landoni, and Andrej Markota, in a correspondence published in Critical Care, challenge the assumption that baseline vasopressor dosage alone can determine whether multimodal vasopressor therapy was administered early or as salvage therapy in septic shock. The researchers addressed critiques regarding the TRICYCLE trial raised by Wieruszewski and Khanna, who had classified the trial intervention as salvage care based primarily on baseline vasopressor requirements and protocol eligibility intervals. The authors demonstrate that treating high vasopressor requirements as synonymous with delayed treatment mischaracterizes clinical trial timelines and obscures crucial distinctions between chronological time and physiological disease trajectory.

In the TRICYCLE trial, the reported median time to randomization was 5.2 hours in the intervention group and 7.1 hours in the control group. Kalamar and colleagues emphasize that this duration was explicitly calculated from the earliest documented hospital presentation with sepsis or septic shock, rather than from the subsequent moment when patients satisfied the protocol’s norepinephrine-equivalent eligibility threshold. Because patients frequently enter the hospital with sepsis before deteriorating into septic shock and eventually requiring vasopressor support, measuring elapsed time from initial presentation captures an earlier clinical window that includes time spent before vasopressor dependency even developed.

The authors further clarify the role of the 12-hour interval permitted under the TRICYCLE trial protocol. While the trial design permitted patient enrollment within 12 hours of reaching the specified vasopressor eligibility threshold, this window defined the outer eligibility boundary rather than the actual elapsed delay before randomization occurred. Consequently, the observed median interval of 5.2 hours cannot be equated with the duration of vasopressor-dependent shock. Instead, it reflects a relatively prompt enrollment process following a patient’s initial presentation to the hospital, contradicting assertions that the intervention was delayed or relegated to salvage management.

To underscore how clinical starting points diverge across critical care literature, the authors contrast TRICYCLE with the benchmark ATHOS-3 trial. Although both trials enrolled patients with comparable vasopressor doses at baseline, their enrollment timelines diverged substantially in clinical definition. While TRICYCLE recorded a median interval of 5.2 hours from initial presentation to randomization in the intervention group, the ATHOS-3 study protocol mandated that patients receive between 6 and 48 hours of vasopressor support exceeding 0.2 micrograms per kilogram per minute of norepinephrine-equivalent prior to enrollment. Furthermore, two external studies cited by Wieruszewski and Khanna in favor of earlier adjunctive initiation defined timing strictly from shock onset rather than from earliest presentation, making direct comparisons misleading.

A central thesis articulated by Kalamar and colleagues is that vasopressor dose indicates the velocity and severity of hemodynamic collapse rather than merely elapsed time. Patients experiencing hyper-acute, rapidly progressive septic shock often escalate to substantial norepinephrine requirements within hours, whereas individuals with slower disease progression can linger below high-dose thresholds for protracted durations. Therefore, observing high vasopressor requirements at baseline does not automatically signify late therapeutic intervention. Equating dosage with time conflates disease severity with therapeutic delay, ignoring the distinct biological trajectories observed in diverse septic shock presentations.

Based on this physiological reality, the researchers caution against imposing rigid upper vasopressor dose ceilings to demarcate early from late therapy in clinical trials. Establishing an arbitrary dosage ceiling risks systematically excluding patients who receive prompt treatment but experience unusually swift hemodynamic deterioration. Such exclusions would eliminate a clinically vital subgroup of critically ill patients who may derive the greatest therapeutic benefit from timely multimodal vasopressor support. Imposing an upper cutoff could inadvertently distort trial populations by favoring patients with indolent shock over those with rapidly advancing circulatory failure.

The importance of timely multimodal therapy across severe shock phenotypes is reinforced by broader clinical evidence. The authors cite a previous meta-analysis of randomized controlled trials demonstrating that the use of non-catecholaminergic vasopressors was associated with improved patient survival across a wide spectrum of vasodilatory shock cohorts, including individuals with established shock. Subsequent analyses highlighted in the correspondence revealed that the early addition of non-catecholaminergic vasopressors was associated with improved survival even among patients receiving high-dose norepinephrine support, supporting the view that advanced shock does not eliminate the potential efficacy of multimodal hemodynamic interventions.

Looking toward future investigational frameworks, the authors acknowledge that comprehensive evaluations of renin-angiotensin system disturbances could help refine patient phenotyping. They also agree that subsequent trials must document treatment timing relative to prior vasopressor exposure in granular detail to delineate optimal initiation windows. Nevertheless, they conclude that defining early intervention requires more sophisticated criteria than single vasopressor dose thresholds. Within its prespecified framework, the TRICYCLE trial evaluated early multimodal vasopressor therapy while proving that chronological timing and vasopressor dosage tell fundamentally different stories in septic shock management.

Subject of Research: Timing and dosage distinctions in multimodal vasopressor therapy for septic shock

Article Title: Timing and dose do not tell the same story: a reply to Wieruszewski and Khanna

Article References: Kalamar, Ž., Landoni, G., & Markota, A. (2026). Timing and dose do not tell the same story: a reply to Wieruszewski and Khanna. Critical Care, 30(1), Article 529. https://doi.org/10.1186/s13054-026-06394-y

Image Credits: AI Generated

DOI: 10.1186/s13054-026-06394-y

Keywords: septic shock, multimodal vasopressor therapy, TRICYCLE trial, vasopressor dosage, treatment timing, norepinephrine, ATHOS-3 trial, hemodynamic deterioration, salvage therapy, critical care medicine, vasodilatory shock, randomization timing, renin-angiotensin system, patient phenotyping, non-catecholaminergic vasopressors, dose ceiling, shock onset, hospital presentation